Salivary Lipid Biomarkers Shifted Toward Typical Levels in Children With Autism After Medical Cannabis Treatment | Research

The takeaway

In an observational study of 15 children with ASD treated with medical cannabis, 22 lipid-based biomarkers in saliva shifted toward levels seen in typically developing children, with network analysis suggesting involvement of inflammation and oxidative stress pathways.

ASD researchers, metabolomics scientists, pediatric cannabis clinicians, biomarker developers.

22 salivary lipid biomarkers shifted toward typical levels after cannabis treatment in ASD

What the researchers found

22 potential lipid-based cannabis-responsive biomarkers shifted toward typically developing (TD) physiological levels after medical cannabis treatment. Members from all five lipid subclasses present in saliva were characterized. Network analysis suggested involvement of inflammation/redox regulation and oxidative stress subnetworks. Sphingomyelin changes may indicate a role of cannabis in neuron function.

Why it matters

ASD treatment response is typically measured by subjective behavioral observation. If salivary lipid biomarkers can objectively track treatment response, it could transform how medical cannabis treatment for ASD is evaluated and optimized.

The numbers in context

N=15 ASD children, N=9 TD controls. 22 lipid-based biomarkers identified. All 5 saliva lipid subclasses represented. THC doses: 0.05-50mg. CBD doses: 7.5-200mg. Treatment duration: 1+ year.

How the study worked

Observational lipidomics study of saliva samples from 15 children with ASD receiving individualized medical cannabis treatment (THC 0.05-50mg, CBD 7.5-200mg) for at least 1 year, compared with 9 age-matched typically developing children.

What this study cannot tell us

Very small sample (15 ASD, 9 TD). Observational design without placebo control. Individualized treatment regimens prevent standardized comparison. Biomarker shifts do not prove clinical improvement. Need larger trials with clinical outcome correlation.

How to read the evidence

Small observational study without placebo control. Novel biomarker approach requiring larger validation studies.

When this study was published

Published in 2023.

The bigger picture

The idea of using saliva metabolomics to objectively measure treatment response is innovative and could apply beyond cannabis to other ASD interventions. The inflammation and oxidative stress pathways identified align with known ASD biology.

Questions still open

Would these biomarkers change similarly in a placebo-controlled trial?
Can salivary lipid biomarkers predict which ASD patients will respond to cannabis treatment?

Common questions

Can saliva tests show if cannabis treatment is working for autism?

This preliminary study found 22 lipid biomarkers in saliva that shifted toward typical levels after cannabis treatment in ASD children, but larger controlled studies are needed to validate this approach.

How does cannabis affect autism biology?

The biomarker patterns suggested cannabis may affect inflammation and oxidative stress pathways, and sphingomyelin changes pointed to possible effects on neuron function.

Read the original research

The Potential of Salivary Lipid-Based Cannabis-Responsive Biomarkers to Evaluate Medical Cannabis Treatment in Children with Autism Spectrum Disorder.

Cannabis and cannabinoid research, 8(4), 642-656

View on PubMed ↗Publisher’s paper ↗

Citation

Siani-Rose, Michael; McKee, Robert; Cox, Stephany; Goldstein, Bonni; Abrams, Donald; Taylor, Myiesha; Kurek, Itzhak. (2023). The Potential of Salivary Lipid-Based Cannabis-Responsive Biomarkers to Evaluate Medical Cannabis Treatment in Children with Autism Spectrum Disorder.. Cannabis and cannabinoid research, 8(4), 642-656. https://doi.org/10.1089/can.2021.0224